Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

NCT04478695 2024-03-08

Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Terminated

1 enrolled 2 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03257722 2024-02-28

PIL

Phase 1/2 Terminated

4 enrolled 5 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT02440425 2022-10-07

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

Phase 2 Completed

42 enrolled 14 charts

Gynecologic

Carcinoma, Ovarian Neoplasms, Recurrence

NCT03168438 2022-01-11

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Phase 1 Terminated

6 enrolled 19 charts

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT02963610 2021-12-30

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

Phase 1/2 Terminated

3 enrolled 5 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT02337491 2020-12-22

Pembrolizumab +/- Bevacizumab for Recurrent GBM

Phase 2 Completed

80 enrolled 13 charts

CNS

NCT02289222 2019-11-05

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

48 enrolled 10 charts

Plasma cell

Multiple Myeloma, Recurrence

Clinical Trials

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts

MK-1454-002

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

PembroWM

HARBOUR

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia

PIL

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

Pembrolizumab +/- Bevacizumab for Recurrent GBM

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma